An Act Regarding Coverage for Step Therapy for Advanced Metastatic Cancer
Introduced
Moved
Reached a final decision
Became law
Derived from the official record below.
Officially: “An Act Regarding Coverage for Step Therapy for Advanced Metastatic Cancer” Read the full text
Official title shown verbatim from the official record. Plain-language summary coming as coverage deepens. Not legal advice.
132nd legislature (2025-2026)HP 111
Where it is
Committee on Health Coverage, Insurance and Financial Services suggested and ordered printed. The Bill was REFERRED to the Committee on HEALTH COVERAGE, INSURANCE AND FINANCIAL SERVICES. Sent for conc · Jan 14, 2025
The Bill was REFERRED to the Committee on HEALTH COVERAGE, INSURANCE AND FINANCIAL SERVICES in concurrence · Jan 14, 2025
Carried over, in the same posture, to the next special or regular session of the 132nd Legislature, pursuant to Joint Order SP 519.^ · Mar 21, 2025
CONSENT CALENDAR - FIRST DAY Under suspension of the rules CONSENT CALENDAR - SECOND DAY. The Bill was PASSED TO BE ENGROSSED as Amended by Committee Amendment "A" (H-272). Sent for concurrence. ORDER · May 27, 2025
Report READ and ACCEPTED, in concurrence. READ ONCE. Committee Amendment "A" (H-272) READ and ADOPTED, in concurrence. Under suspension of the Rules, READ A SECOND TIME and PASSED TO BE ENGROSSED AS A · May 28, 2025
PASSED TO BE ENACTED. Sent for concurrence. ORDERED SENT FORTHWITH. · May 29, 2025
On motion by Senator ROTUNDO of Androscoggin PLACED ON THE SPECIAL APPROPRIATIONS TABLE pending ENACTMENT in concurrence. · Jun 2, 2025
On motion by Senator ROTUNDO of Androscoggin taken from the Special Appropriations Table PASSED TO BE ENACTED in concurrence. · Jun 25, 2025
The numbers
3
sponsors on the bill
Sponsors
Kristi MathiesonDenise TeplerSally Cluchey
Every fact on this page links to its source, starting with the official bill record. Last action: On motion by Senator ROTUNDO of Androscoggin taken from the Special Appropriations Table PASSED TO BE ENACTED in concurrence. (Jun 25, 2025).